Meningococcal Conjugate Vaccine Studies May Use Immunologic Correlates
Executive Summary
Immunologic correlates may be used to predict protective efficacy of meningococcal conjugate vaccines, FDA's Vaccines and Related Biological Products Advisory Committee agreed at a Sept. 15 meeting in Bethesda, Md.
You may also be interested in...
Pediatric Meningococcal Vaccine's Approval Pathway May Work For Other Disease Areas
FDA suggests serum bactericidal antibody measurements to predict protection from meningococcal diseases in children under age 2.
Abbott Ends Certiva Agreement In U.S.; NAVA Focuses on NeisVac-C for U.K.
Abbott has terminated its agreement with North American Vaccine to market its combination diphtheria, tetanus and acellular pertussis vaccine Certiva to private physicians in the U.S.
Abbott Ends Certiva Agreement In U.S.; NAVA Focuses on NeisVac-C for U.K.
Abbott has terminated its agreement with North American Vaccine to market its combination diphtheria, tetanus and acellular pertussis vaccine Certiva to private physicians in the U.S.